Media stories about Dynavax Technologies Corporation (NASDAQ:DVAX) have been trending somewhat positive on Wednesday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dynavax Technologies Corporation earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.7844167211978 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- Investors Traded Stock: Dynavax Technologies Corporation (DVAX) - Morning Times (wallstreetmorning.com)
- Dynavax Technologies Corporation (DVAX)- Stocks Rallying on Glossy Performance Valuation - NASDAQ Times (nasdaqtimes.com)
- Dynavax Technologies Corporation (DVAX) has a value of $9.70 per share While Affimed NV (AFMD) is stand at $2.45 - Stocks Gallery (stocksgallery.com)
- Alliancebernstein LP Reduces Stake in Carpenter Technology Corporation (NYSE:CRS) (overnewsmagazine.com)
- Stock Performance Check on Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) - Jonesboro Recorder (jonesbororecorder.com)
A number of equities analysts have weighed in on DVAX shares. Royal Bank Of Canada upped their price target on Dynavax Technologies Corporation from $6.00 to $7.00 and gave the stock a “sector perform” rating in a research report on Tuesday, May 9th. ValuEngine downgraded Dynavax Technologies Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Zacks Investment Research raised Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Monday, July 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $19.20.
Dynavax Technologies Corporation (NASDAQ:DVAX) traded down 2.08% during midday trading on Wednesday, hitting $9.40. The stock had a trading volume of 1,160,448 shares. The stock’s 50-day moving average is $8.51 and its 200-day moving average is $5.97. The stock’s market capitalization is $458.65 million. Dynavax Technologies Corporation has a 1-year low of $3.20 and a 1-year high of $17.50.
Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.60). Dynavax Technologies Corporation had a negative return on equity of 100.45% and a negative net margin of 1,080.18%. The business had revenue of $0.15 million during the quarter, compared to the consensus estimate of $0.75 million. During the same quarter in the prior year, the company posted ($0.70) earnings per share. On average, equities research analysts anticipate that Dynavax Technologies Corporation will post ($1.47) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://stocknewstimes.com/2017/07/19/dynavax-technologies-corporation-dvax-receiving-somewhat-positive-media-coverage-report-finds.html.
Dynavax Technologies Corporation Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
